<DOC>
	<DOCNO>NCT00313924</DOCNO>
	<brief_summary>OAB widespread medical problem affect 6- 30 % population ( sexes age group ) Europe1 16 % 2-18 % 3 US Canadian population . Nevertheless small proportion group turn seek medical help . Once treat , evaluation treatment outcome problematic since outcome measure success vary widely ( i.e . improvement number incontinence episode , number urge episode , change frequency nocturia etc ) include measure patient report outcome . The OAB Assessment Tool self-administered questionnaire ( 8-question self–filled survey ) primarily intend identify patient symptoms OAB . The comparable information could obtain certain treatment period , thus provide accurate precise measure success . It could also offer insight change different parameter make problem . Due ease administration high specificity assess OAB , OAB Assessment Tool seem optimal objective .</brief_summary>
	<brief_title>Assessing OAB-8 Questionnaire Tool Measure Treatment Outcome</brief_title>
	<detailed_description>This study non-randomised , non-placebo control prospective clinical trial . We intend recruit approximately 100 patient receive fill questionnaire medical treatment detrusitol 4mg . Study protocol receive approval local ethical committee . Method : Twenty general practitioner ( GP ) actively participate recruitment treatment patient . After brief inquiry , patient urinary complaint offer option complete OAB-V8 questionnaire participate trial eligible . After patient fill OAB-V8 find fit study , patient receive accurate information regard study sign inform consent form . Protocol : The study consist 2 visit , visit 1 pre visit 2 post-treatment Detrusitol 4mg . Visit I : Randomly select patient request complete OAB –V8 questionnaire . Those score &gt; 8 point eligible inclusion . They complete informed consent form undergo basic medical history . Patients give treatment detrusitol 4mg daily ( total 28 tablet ) . They also require fill voiding/frequency urgency chart three day prior commence treatment three day finish treatment period ( day 25 treatment period ) confirm diagnosis OAB . Patients also ask question lab work perform rule patient Urinary Conditions . Information side effect contact number 24/7 question problem arise provide . After end one-month treatment , patient return 2nd final visit . Twenty-eight tablet Detrusitol 4mg provide every patient . Visit II : Patients evaluate regard effect treatment complete OAB-V8 questionnaire . On visit , accord physician ’ professional consideration , satisfied patient receive prescription Detrusitol 4mg continue treatment . The statistical method employ include Chi Square Fisher exact test , logistic regression ( logistic run mainly covariates age , gender baseline symptom severity score predict achieve 10 point change symptom bother scale . Software utilised include SAS JMP .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<criteria>1 . OAB score ≥ 8 2 . Age 2080 year old 3 . Patients must comply agree requirement take Detrusitol 4mg new medication affect low urinary tract system Exclusion criterion : 1 . Patients treatment ( whether medical conservative ) OAB . 2 . Patients document UTI . 3 . Patients demonstrated hypersensitivity drug ingredient . 4 . Where Detrusitol contraindicate ( i.e . patient severe outlet obstruction , gastric retention , uncontrolled narrowangle glaucoma ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>URGENCY FREQUENCY SYNDROME</keyword>
	<keyword>URGE INCONTINENCE</keyword>
</DOC>